CAR Macrophages in Brain Tumor Immunotherapy: Molecular Engineering Strategies and Emerging Frontiers
Year: 2026
Type: article
Abstract: The CNS is partly shielded from immune attack, which allows tumor cells to escape many conventional therapies, including CAR-T. CAR-M therapy is an alternative approach that exploits the ability of myeloid cells to enter the CNS, engulf tumor cells, and shift the immunosuppressive microenvironment. This review focuses on molecular engineering principles for next-generation CAR-M constructs, including signaling domain selection, CD47-SIRPα checkpoint strategies, and gene delivery platforms for myeloid cells. We also discuss CNS-specific delivery routes and the multi-layered anti-tumor mechanisms of CAR-M, such as phagocytosis, TME remodeling, and innate–adaptive immune bridging. Combination strategies with checkpoint inhibitors, oncolytic viruses, and chemotherapy are analyzed, together with emerging approaches like SIGLEC9-based chimeric switch receptors, enucleated MSC-mediated in situ CAR-M generation, and circRNA-based CAR expression. We then address CNS-specific safety considerations and translational challenges.
Source: Biomolecules
DOI: 10.3390/biom16111650
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,258
Award: G1121948032
OpenAlex ID: W7225920018
